Ian A. Wilson

This study affinity-matures an antibody to recognize both MUC1-Tn and MUC1-STn glycoforms, enhancing its efficacy against heterogeneous tumors.

This study shows that sequential vaccination can mature VRC01-class B cells into antibodies that neutralize a broad range of HIV-1 viruses.

This study shows that xenoglycosylation of HIV-1 Env with core (1,3)-fucose enhances cross-clade neutralization and diversifies human antibody lineages.

This study identifies potent antimalarial antibodies in African infants vaccinated with RTS,S/AS01E, showing near-germline configurations and protective efficacy.

This study evaluates CMX990, a coronavirus Mpro inhibitor, showing broad antiviral activity against multiple coronaviruses and superior pharmacologic properties compared to existing inhibitors.

This paper designs de novo minibinders that inhibit blood-stage malaria replication with nanomolar potency by targeting the RH5-basigin interaction.

This study designs stabilized HA trimers on self-assembling protein nanoparticles to improve influenza vaccine efficacy by enhancing immunogenicity and lymph node retention.

Epitope-focused S2 stem-helix nanoparticle immunogens elicit protective broadly neutralizing antibodies against diverse betacoronaviruses in non-human primates, establishing a framework for pan-betacoronavirus vaccines.

This paper describes the directed evolution of an antibody to enhance its binding affinity for MERS-CoV, resulting in cross-neutralization against multiple betacoronaviruses.

This study identifies the conserved bridging domain on HCV E1E2 as a target for neutralizing antibodies from diverse lineages, showing additivity with neutralizing face antibodies.

This study investigates the antiviral activity and mechanism of 4'-fluoroadenosine against viral and host polymerases, showing broad-spectrum inhibition and potential for drug development.

This study shows that inhibiting SagA, a peptidoglycan hydrolase, increases vancomycin susceptibility in VREfm through both genetic and pharmacological approaches.

This study characterizes the structure and function of antibodies targeting the conserved β-epitope region of PfCSP, showing how they achieve strain-transcending recognition and enhance Fc-mediated immune responses.

This study determines the structural basis of antigen recognition by two mAbs targeting PfCSP, revealing conserved and distinct binding modes and their implications for antibody function.

This study identifies two classes of HCV E2 neutralizing antibodies from non-human primates immunized with a recombinant E1E2, showing similarity to human antibodies.

This study uses deep learning to design multi-epitope scaffolds mimicking CSP's spatial structure, showing accurate positioning of two epitopes and partial success with the third.

This study identifies a cross-reactive germline antibody that can be evolved to neutralize multiple SARS-CoV-2 variants through targeted somatic mutations.

This study identifies an immunodominant S2 apex epitope in SARS-CoV-2 that elicits a public antibody clonotype, highlighting its role as a barrier to universal coronavirus vaccines.

This study vaccinates nonhuman primates with SARS-CoV-2 and MERS-CoV spike proteins to elicit cross-reactive antibodies that neutralize both sarbecoviruses and merbecoviruses.

This study identifies that H5Nx influenza A viruses bind promiscuously to avian-type mucin-like O-glycans, enhancing their zoonotic potential by binding human tracheal tissues.

This study determines the structure of HAstV spikes bound to FcRn, identifies conserved epitopes, and suggests repurposing FcRn inhibitors for antiviral therapy.

This paper describes the engineering of high-affinity 3-phosphohistidine-specific antibodies using phage display and validates their utility in detecting pHis proteins in mammalian cells.

This study identifies a monoclonal antibody that neutralizes HCoV-HKU1 by mimicking sialic acid binding to block receptor engagement.

This study characterizes a broad-neutralizing influenza antibody, 1122A11, showing it neutralizes multiple NA subtypes and adapts to recent glycosylation changes in H3N2 viruses.

This study shows that HIV Env trimers coupled to liposomes induce cross-neutralizing antibodies in NHPs that mimic human bNAbs targeting the Env trimer apex.

This paper describes VYD222, a broadly neutralizing antibody effective against SARS-CoV-2 variants, including Omicron, and explains its structural basis for resistance to viral escape.

The paper determines the crystal structures of engineered monoclonal antibodies MAM01 and MS-1805 in complex with Plasmodium falciparum CSP, showing retained binding affinity and no significant conformational changes.

This paper reports structural analysis of VRC01-class bnAb precursors from a vaccine trial, showing they bind HIV Env with germline-like features and glycan adaptability.

This study shows that CR3022-like antibodies can be evolved in vivo through vaccination to neutralize SARS-CoV-2 and related viruses by enhancing affinity and breadth.

The paper examines how mutations and a deletion in the KP.3.1.1 SARS-CoV-2 spike protein affect ACE2 binding and antibody escape, revealing structural and functional insights into its evolution.